Linagliptin Sandoz

Linagliptin, the active ingredient in Linagliptin Sandoz, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Linagliptin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin Sandoz belongs to the DPP‑4 inhibitor class used to improve glycaemic control in type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers elevated blood glucose levels when combined with diet and exercise, either as monotherapy or as add‑on therapy.

Common Side Effects: - Nasopharyngitis: mild inflammation of the upper airway. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Dizziness: occasional light‑headed sensation. - Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia (when combined with insulin or sulfonylureas): symptomatic low blood sugar. - Bullous pemphigoid: rare autoimmune skin disorder.

Before initiating therapy, consider the following precautions: - Renal function monitoring: assess baseline and periodic kidney function. - Pancreatitis vigilance: discontinue if signs of acute pancreatitis appear. - Concomitant hypoglycaemic agents: adjust dose to avoid low blood glucose. - Elderly patients: start at the lowest effective dose and monitor closely. - Known hypersensitivity: avoid if patient has experienced allergic reactions to linagliptin or any excipients. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Linagliptin may interact with several drug classes. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin effectiveness. - Insulin or sulfonylureas: heightened risk of hypoglycaemia. Moderate Interactions (Monitor Closely): - Diuretics: possible alteration of glucose control. - NSAIDs: may affect renal function when combined. - ACE inhibitors: monitor blood pressure and renal parameters. - Warfarin: observe INR values for potential changes.